$EYPT News Article - EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting
https://marketwirenews.com/news-releases/eyep...25407.html